Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03000179
Recruitment Status : Active, not recruiting
First Posted : December 21, 2016
Last Update Posted : August 21, 2019
National Cancer Institute (NCI)
EMD Serono
Information provided by (Responsible Party):
Dana Cardin, MD, Vanderbilt-Ingram Cancer Center

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : April 15, 2022
Estimated Study Completion Date : April 15, 2023